Suvoda Unveils Agentic RTSM to Reduce Clinical Trial Preparation by 80%

Suvoda's Revolutionary Agentic RTSM Technology

In the world of clinical research, time is of the essence. Traditional processes can often lead to lengthy delays between contract signing and the commencement of clinical trials. Suvoda, a global leader in clinical trial technology, has unveiled an innovative solution: agentic RTSM (Randomization and Trial Supply Management). This advanced system is poised to transform the landscape of clinical study preparation by significantly reducing the time required to launch trials, allowing sponsors to deliver vital therapies to patients more efficiently.

The Need for Speed in Clinical Trials

Bringing a new treatment to market is a complex process that involves rigorous testing and validation. For sponsors, the preparatory phase often represents one of the most time-consuming aspects of the overall process. It can take months to transition from a signed agreement to the first patient being enrolled in a study. Such delays can result in lost opportunities for patients who urgently need new therapies.

Recognizing this challenge, Suvoda has developed its agentic RTSM, the latest evolution of its IRT platform. This groundbreaking system leverages cutting-edge agent-based AI technology to streamline the clinical trial setup process. According to Suvoda, agents can accelerate the timeline from project initiation to User Acceptance Testing (UAT) by as much as 80%.

Key Advantages of Agentic RTSM

Suvoda's agentic RTSM provides several tangible benefits for sponsors and clinical teams:

1. Faster Study Preparation: By utilizing advanced AI agents, the time taken for project initiation to UAT is drastically reduced.
2. Enhanced Experiences for Sponsors and Sites: Quick access to study information minimizes administrative burdens and improves engagement with clinical centers.
3. Improved Insights and Decision-Making: The system offers enhanced transparency regarding study status and supports smarter decision-making processes for teams.

By using multiple AI agents to oversee various phases of study preparation—including software configuration and testing—Suvoda's new approach is set to transform how clinical trials are executed. Rather than building systems from scratch for each study, agentic RTSM draws upon a pre-existing data layer created from Suvoda's extensive experience with thousands of complex studies. This allows for rapid deployment and efficient management of trial operations.

The Role of AI in Clinical Research

Jagath Wanninayake, CEO of Suvoda, emphasized the goal of minimizing operational friction in the study startup process through technology: "Clinical trials are becoming increasingly complex and urgent, and our clients should not have to struggle with technologies that slow them down. With agentic RTSM, we eliminate bottlenecks, allowing sponsors to begin recruiting patients sooner and providing a more responsive experience for clinical centers."

Currently, Suvoda is collaborating with select early adopters to implement the agentic RTSM features, reinforcing the operational and service foundations for a broader rollout. Additionally, improvements to Suvoda's AI assistant, Sofia, are underway. Sofia is designed to support monitoring, issue alerts, and take direct actions while adhering to strict safety considerations. The company plans to extend this agentic model to other services, including electronic Clinical Outcome Assessments (eCOA) and financial products, further enhancing the speed and consistency of various study components.

The Bigger Picture

E.K. Koh, the Senior Product Manager at Suvoda, articulated the overarching vision for their AI-driven technological advancements: "Our aim is to make every moment in a study smarter, whether answering protocol changes or supporting study coordinators in finding the right solutions in seconds. The agent-based RTSM is a significant step toward our broader AI vision, ensuring that speed, quality, and experience are enhanced simultaneously."

Suvoda's commitment goes beyond merely improving efficiency in clinical trials; it reflects a deep dedication to facilitating expedited access to therapies for patients in need. A quicker study start is not just an operational metric but a vital contributor to delivering essential medications sooner, ultimately saving lives.

About Suvoda

Suvoda is a pioneering global technology firm specializing in clinical trials. They provide a leading-edge real-time software platform that aids sponsors and Contract Research Organizations (CROs) in making safe decisions while enabling research sites and patients to conduct trials smoothly and effectively. With headquarters in the Philadelphia metropolitan area and additional locations across the globe, including Europe and Asia, Suvoda is dedicated to improving the clinical trial landscape, supporting over 6,000 studies in more than 115 countries. Recently, they merged with Greenphire, a leader in financial management and patient support tools for clinical studies. For more information, visit suvoda.com and follow Suvoda on LinkedIn.